Antibody fragments as tools in crystallography

Clinical and Experimental Immunology

Volumn 165, Issue 3, 2011, Pages 285-291

  Griffin, L ^a   Lawson, A ^a  

^a UCB Celltech   (United Kingdom)

Author keywords

Antibodies; Antibody mediated crystallization; Crystallography; Fragments

Indexed keywords

ANTIBODY; CHAPERONE; PERTUZUMAB; SCAFFOLD PROTEIN; TRASTUZUMAB;

ANTIBODY STRUCTURE; CRYSTAL STRUCTURE; CRYSTALLIZATION; CRYSTALLOGRAPHY; DRUG INDUSTRY; GENETIC ENGINEERING; MEDICAL TECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; PROTEIN TARGETING; REVIEW;

CRYSTALLOGRAPHY; DRUG DISCOVERY; IMMUNOGLOBULIN FRAGMENTS; PROTEIN STABILITY;

EID: 79960976700     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04427.x     Document Type: Review

References (59)

1. Jhoti H. Fragment-based drug discovery using rational design. Ernst Schering Found Symp Proc 2007; 3:169-85.
2. Hajduk PJ, Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 2007; 6:211-19.
3. Derewenda ZS. The use of recombinant methods and molecular engineering in protein crystallization. Methods 2004; 34:354-63.
4. Anderson J, Ptashne M, Harrison SC. Cocrystals of the DNA-binding domain of phage 434 repressor and a synthetic phage 434 operator. Proc Natl Acad Sci USA 1984; 81:1307-11.
5. Hunte C, Michel H. Crystallisation of membrane proteins mediated by antibody fragments. Curr Opin Struct Biol 2002; 12:503-8.
6. Lustbader JW, Birken S, Pileggi NF etal. Crystallization and characterisation of human chorionic gonadotropin in chemically deglycosylated and enzymatically desialylated states. Biochemistry 1989; 28:9239-43.
7. Privé GG, Kaback HR. Engineering the lac permease for purification and crystallization. J Bioenerg Biomembr 1996; 28:29-34.
8. Cherezov V, Rosenbaum DM, Hanson MA etal. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007; 318:1258-65.
9. 3 ubiquinol oxidase from Escherichia coli. Biochim Biophys Acta 2000; 1459:449-55.
10. Koide S. Engineering of recombinant crystallization chaperones. Curr Opin Struct Biol 2009; 19:449-57.
11. Sennhauser G, Grütter MG. Chaperone-assisted crystallography with DARPins. Structure 2008; 16:1443-53.
12. Gill DS, Damle NK. Biopharmaceutical drug discovery using novel protein scaffolds. Curr Opin Biotechnol 2006; 17:653-8.
13. Skerra A. Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol 2007; 18:295-304.
14. Tolmachev V, Orlova A, Nilsson FY etal. Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Exp Opin Biol Ther 2007; 7:555-68.
15. Binz HK, Amstutz P, Plückthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 2005; 23:1257-68.
16. Eigenbrot C, Ultsch M, Dubnovitsky A, Abrahmsén L, Härd T. Structural basis for high affinity HER2 receptor binding by an engineered protein. Proc Natl Acad Sci USA 2010; 107:15039-44.
17. Bandeiras TM, Hillig RC, Matias PM etal. Structure of wild-type Plk-1 kinase domain in complex with a selective DARPin. Acta Crystallogr D Biol Crystallogr 2008; 64:339-53.
18. Derewenda ZS, Vekilov PG. Entropy and surface engineering in protein crystallization. Acta Crystallogr D Biol Crystallogr 2006; 62:116-24.
19. Grubisha O, Kaminska M, Duquerroy S etal. DARPin-assisted crystallography of the CC2-LZ domain of NEMO reveals a coupling between dimerisation and ubiquitin binding. J Mol Biol 2010; 395:89-104.
20. Lo YC, Lin SC, Rospigliosi CC etal. Structural basis for recognition of diubiquitins by NEMO. Mol Cell 2009; 33:602-15.
21. Rahighi S, Ikeda F, Kawasaki M etal. Specific recognition of linear ubiquitin chains by NEMO is important for NF-κB activation. Cell 2009; 136:1098-109.
22. Kohl A, Amstutz P, Parizek P etal. Allosteric inhibition of aminoglycoside phosphotransferase by a designed ankyrin repeat protein. Structure 2005; 13:1131-41.
23. Schweizer A, Roschitzki-Voser H, Amstutz P etal. Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure and inhibition mechanism. Structure 2007; 15:625-36.
24. Schweizer A, Briand C, Grütter MG. Crystal structure of caspase-2 apical initiator of the intrinsic apoptotic pathway. J Biol Chem 2003; 278:42441-7.
25. +-citrate symporter CitS as an example. J Struct Biol 2007; 159:206-21.
26. Veesler D, Dreier B, Blangy S etal. Crystal structure and function of a DARPin neutralising inhibitor of lactococcal phage TP901-1. J Biol Chem 2009; 284:30718-26.
27. HH) scaffold. Protein Sci 2008; 17:1175-87.
28. Ermolenko DN, Zherdev AV, Dzantiev BB, Popov VO. Antiperoxidase antibodies enhance refolding of horseradish peroxidase. Biochem Biophys Res Commun 2002; 291:959-65.
29. Uysal S, Vásquez V, Tereshko V etal. Crystal structure of full-length KcsA in its closed conformation. Proc Natl Acad Sci USA 2009; 106:6644-9.
30. Air GM, Webster RG, Colman PM, Laver WG. Distribution of sequence differences in influenza N9 neuraminidase of tern and whale viruses and crystallization of the whale neuraminidase complexed with antibodies. Virology 1987; 160:346-54.
31. Prongay AJ, Smith TJ, Rossmann MG etal. Preparation and crystallization of a human immunodeficiency virus p24-Fab complex. Proc Natl Acad Sci USA 1990; 87:9980-4.
32. Jacobo-Molina A, Clark JAD, Williams RL etal. Crystals of a ternary complex of human immunodeficiency virus type 1 reverse transcriptase with a monoclonal antibody Fab fragment and double-stranded DNA diffract X-Rays to 3·5Å resolution. Proc Natl Acad Sci USA 1991; 88:10895-9.
33. Kovari LC, Momany C, Rossmann MG. The use of antibody fragments for crystallization and structure determinations. Structure 1995; 3:1291-3.
34. Kortt AA, Malby RL, Caldwell JB etal. Recombinant anti-sialidase single-chain variable fragment antibody. Characterisation, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex. Eur J Biochem 1994; 221:151-7.
35. 1 complex from the yeast Saccharomyces cerevisiae co-crystallized with an antibody Fv fragment. Structure 2000; 8:669-84.
36. Ostermeier C, Iwata S, Ludwig B, Michel H. Fv fragment-mediated crystallization of the membrane protein bacterial cytochrome c oxidase. Nat Struct Biol 1995; 2:842-46.
37. Ostermeier C, Harrenga A, Ermler U, Michel H. Structure at 2·7Å resolution of the Paracoccus denitrificans two-subunit cytochrome c oxidase complexed with an antibody Fv fragment. Proc Natl Acad Sci USA 1997; 94:10547-53.
38. + channel-Fab complex at 2·0Å resolution. Nature 2001; 414:43-8.
39. Tegoni M, Spinelli S, Verhoeyen M, Davis P, Cambillau C. Crystal structure of a ternary complex between human chorionic gonadotropin (hCG) and two Fv fragments specific for the α and β-subunits. J Mol Biol 1999; 289:1375-85.
40. Sumner JB. The isolation and crystallization of the enzyme urease. J Biol Chem 1926; 69:435-41.
41. Sheridan L, Wilmot CM, Cromie KD, van der Logt P, Phillips SEV. Crystallization and preliminary X-ray structure determination of jack bean urease with a bound antibody fragment. Acta Crystallogr Sect D Biol Crystallogr 2002; 58:374-6.
42. Li H, Dunn JJ, Luft BJ, Lawson CL. Crystal structure of Lyme disease antigen outer surface protein A complexed with an Fab. Proc Natl Acad Sci USA 1997; 94:3584-9.
43. Jiang Y, Lee A, Chen J etal. X-Ray structure of a voltage-dependent K+ channel. Nature 2003; 423:33-41.
44. McKinstry WJ, Polekhina G, Diefenbach-Jagger H etal. Crystallization of the receptor-binding domain of parathyroid hormone-related protein in complex with a neutralising monoclonal antibody Fab fragment. Acta Crystallogr Sect F Struct Biol Cryst Commun 2009; 65:336-8.
45. Rasmussen SG, Choi H-J, Rosenbaum DM etal. Crystal structure of the human beta2 adrenergic G protein-coupled receptor. Nature 2007; 450:383-7.
46. Granata V, Housden NG, Harrison S etal. Comparison of the crystallization and crystal packing of two Fab single-site mutant protein L complexes. Acta Crystallogr D Biol Crystallogr 2005; 61:750-4.
47. Roosild TP, Castronovo S, Choe S. Structure of anti-FLAG M2 Fab domain and its use in the stabilization of engineered membrane proteins. Acta Crystallogr Sect F Struct Biol Cryst Commun 2006; 62:835-9.
48. Pai JC, Culver JA, Drury JE etal. Conversion of scFv peptide-binding specificity for crystal chaperone development. Protein Eng Des Sel 2011; 24:419-28.
49. Hamers-Casterman C, Atarhouch T, Muyldermans S etal. Naturally occurring antibodies devoid of light chains. Nature 1993; 363:446-8.
50. Desmyter A, Transue TR, Ghahroudi MA etal. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat Struct Biol 1996; 3:803-11.
51. Lauwereys M, Ghahroudi MA, Desmyter A etal. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J 1998; 17:3512-20.
52. Loris R, Marianovsky I, Lah J etal. Crystal structure of the intrinsically flexible addiction antidote MazE. J Biol Chem 2003; 278:28252-7.
53. Kamada K, Hanaoka F, Burley SK. Crystal structure of the MazE/MazF complex: molecular bases of antidote-toxin recognition. Mol Cell 2003; 11:875-84.
54. Yanez ME, Korotkov KV, Abendroth J, Hol WG. The crystal structure of a binary complex of two pseudopilins: EpsI and EpsJ from the type 2 secretion system of Vibrio vulnificus. J Mol Biol 2008; 375:471-86.
55. Lam AY, Pardon E, Korotkov KV, Hol WGJ, Steyaert J. Nanobody-aided structure determination of the EpsI:EpsJ pseudopilin heterodimer from Vibrio vulnificus. J Struct Biol 2009; 166:8-15.
56. Korotkov KV, Pardon E, Steyaert J, Hol WGJ. Crystal structure of the N-terminal domain of the secretin GspD from ETEC determined with the assistance of a nanobody. Structure 2009; 17:255-65.
57. De Genst E, Guilliams T, Wellens J etal. Structure and properties of a complex of α-synuclein and a single-domain camelid antibody. J Mol Biol 2010; 402:326-43.
58. Domanska K, Vanderhaegen S, Srinivasan V etal. Atomic structure of a nanobody-trapped domain-swapped dimer of an amyloidogenic beta2-microglobulin variant. Proc Natl Acad Sci USA 2011; 108:1314-19.
59. 2 adrenoceptor. Nature 2011; 469:175-81.